Published: July’ 2017 This report is an essential source of data and trend analysis on M&A (mergers, acquisitions, and asset transactions), in the upstream oil and gas industry. The report provides detailed comparative month-on-month data, on the number of deals and their value, sub-divided into deal types by geographies. It also envisage on the recent…
Monthly Upstream Capital Raising Review – June 2017
Published: July’ 2017 This report is an essential source of data and trend analysis on financings (equity/debt offerings and PE/VC) in the upstream oil and gas industry. The report provides detailed comparative month-on-month data, on the number of deals and their value, sub-divided into deal types by geographies. Data presented in this report is derived…
Monthly Oil & Gas Industry Contracts Review – Coral FLNG and Amur Gas Processing Construction Boosts Contract Activity in EMEA Region
Published: July’ 2017 The report is an essential source of data on the contracts and open tenders in the oil and gas industry, The report portrays detailed comparative data on the number of contracts and their value in the month, subdivided by region, sector and geographies in June 2017, Additionally, the report provides information on…
Pharmapremia Oncology Success Rates Scorecard
DESCRIPTION Over the past five years, oncology drug development has increased dramatically as a proverbial arms-race accelerated into the immune-oncology space. Some of the biggest names in Pharma began development internally, and scoured the globe for in-licensing and acquisition candidates to stake their claim to the next-generation of cancer standard of care. With Oncology drug…
Immuno-Oncology Deal Trends, 2012–16
DESCRIPTION Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups signed more than 300 immuno-oncology deals between 2012 and 2016, growing at…
NOACs Pricing, Reimbursement, and Access
DESCRIPTION A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers. The impact of NOACs on European budgets is so great that a UK payer…
Global Influenza Drugs and Vaccines Market – By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) – Analysis By Region, By Country: Opportunities and Forecast (2016-2021)- – By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan)
EXECUTIVE SUMMARY A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Influenza Market on the basis of Segment Type (Vaccine and Drugs), By Vaccine (Trivalent and Quadrivalent), By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Region (North America,…
Q4 2016 Outlook Report – Cover Catalysts from 23 Drugs, Devices and Diagnostics
In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q4 2016. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular…
Pharmaceuticals & Healthcare – Upcoming & Recent Reports
OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-… Published: May’ 2017 Format: Electronic PDF Pricing:…
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals
“Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered…
Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals
“Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered…
Medical Imaging Market in India 2017
Medical Imaging Market in India 2017 states that the market for medical imaging devices in India will witness strong growth in the next five years. Medical imaging can be classified into five broad segments, namely, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Imaging, Ultrasound and X-Ray. MRI accounts for the highest share followed by…
